BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay
Introduction: The role of infiltrating cells (I.C.), commonly observed in the adenoma interstitial tissue, is unknown. We tested the hypothesis that I.C. are related with BPH progression by: phenotypically characterising these cells; quantifying the expression of lymphokines and growth factors; inve...
Gespeichert in:
| Veröffentlicht in: | European urology 2003-11, Vol.44 (5), p.549-555 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 555 |
|---|---|
| container_issue | 5 |
| container_start_page | 549 |
| container_title | European urology |
| container_volume | 44 |
| creator | Vela Navarrete, R Garcia Cardoso, J.V Barat, A Manzarbeitia, F López Farré, A |
| description | Introduction:
The role of infiltrating cells (I.C.), commonly observed in the adenoma interstitial tissue, is unknown. We tested the hypothesis that I.C. are related with BPH progression by: phenotypically characterising these cells; quantifying the expression of lymphokines and growth factors; investigating the response to Permixon (P) in a clinical study. Permixon is a Lipido Sterolic Extract of Serenoa repens possessing pharmacological activities and widely used in the treatment of men with BPH.
Material and Methods:
A multicenter open pilot study of two parallel groups on BPH patients was carried out. They were randomized to receive either oral Permixon (P) 160
mg bid for three months or to be followed for 3 weeks without any treatment before surgery (control group C). Strict inclusion and exclusion criteria were applied to conform homogeneous groups, avoiding interferences of inflammatory drugs or others. Baseline clinical profile was almost identical in both groups in terms of age (65.7±5.1 vs. 67.1±5.8 years), IPSS (19.8±6.1 vs. 19.0±5.8), prostate volume (64.8±18.9 vs. 71.5±29.3
cc),
Q
max (9.6±3.2 vs. 10.6±2.6
ml/s), and
Q
L (4.0±1.1 vs. 3.5±0.7). Surgery was ultimately performed on 29 patients (17C, 12P) by TURP or retropubic adenomectomy. Adenoma samples were routinely stained with HE and later prepared for immunohistochemical studies using CD3, CD20 and CD68 antibodies. Counting of positives cells, lymphoid aggregates and foci were done using EnVision technique and the Tech Mate processor. Cytokines, growth factors and eicosanoids were determined by Elisa kits following the manufactured recommendation.
Results:
Histological: A difference was observed in the number of lymphocytes B between C (91.4±44.1) and P treated (58.2±53.7) groups (
p=0.097).
Biological markers: TNFα and IL-1β were dramatically lower in the Permixon treated group. Other parameters did not show significant changes.
Clinical: IPSS in the Permixon treated group was significantly reduced (
p |
| doi_str_mv | 10.1016/S0302-2838(03)00368-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71314514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283803003683</els_id><sourcerecordid>71314514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-8c0d9908adc48ef29eef78d1a36ba934511dc7307f24e39e7356829a72590a6e3</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhS0EokPhJ4C8oYJFih9JnLBB7VA6lVox4rG27jjXYHDi1k4Q81_4sXge6iwrWbIX3zm-9xxCXnJ2yhmv331lkolCNLJ5w-RbxmTdFPIRmfFGyUJVNXtMZvfIEXmW0i-WqaqVT8kRLyslVCVn5N_5ckFh6OjVYD30PYwuDO_p8ifEHkzw4Ycz4OmFtWjGRIOlS4y9-xsGms_CpfGe2bjcBI9m8hAPfiGu6Q3E3xjTKf2CafI7H6Afw7TySM-9y8ql82Gk8_zemp2lBOvn5IkFn_DF_j4m3z9dfJsviuvPl1fzs-vCyJaPRWNY17asgc6UDVrRIlrVdBxkvYJWlhXnnVGSKStKlC0qWdWNaEGJqmVQozwmJzvf2xjuJkyj7l0y6D0MGKakFZc5MV5msNqBJoaUIlp9G10Pca0505ta9LYWvclcM6m3tWiZda_2H0yrHruDat9DBl7vAUh5fRthMC4duEqIkpebAT7sOMxx_HEYdTIOB4Odi7kg3QX3wCj_Aeevqq0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71314514</pqid></control><display><type>article</type><title>BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Vela Navarrete, R ; Garcia Cardoso, J.V ; Barat, A ; Manzarbeitia, F ; López Farré, A</creator><creatorcontrib>Vela Navarrete, R ; Garcia Cardoso, J.V ; Barat, A ; Manzarbeitia, F ; López Farré, A</creatorcontrib><description>Introduction:
The role of infiltrating cells (I.C.), commonly observed in the adenoma interstitial tissue, is unknown. We tested the hypothesis that I.C. are related with BPH progression by: phenotypically characterising these cells; quantifying the expression of lymphokines and growth factors; investigating the response to Permixon (P) in a clinical study. Permixon is a Lipido Sterolic Extract of Serenoa repens possessing pharmacological activities and widely used in the treatment of men with BPH.
Material and Methods:
A multicenter open pilot study of two parallel groups on BPH patients was carried out. They were randomized to receive either oral Permixon (P) 160
mg bid for three months or to be followed for 3 weeks without any treatment before surgery (control group C). Strict inclusion and exclusion criteria were applied to conform homogeneous groups, avoiding interferences of inflammatory drugs or others. Baseline clinical profile was almost identical in both groups in terms of age (65.7±5.1 vs. 67.1±5.8 years), IPSS (19.8±6.1 vs. 19.0±5.8), prostate volume (64.8±18.9 vs. 71.5±29.3
cc),
Q
max (9.6±3.2 vs. 10.6±2.6
ml/s), and
Q
L (4.0±1.1 vs. 3.5±0.7). Surgery was ultimately performed on 29 patients (17C, 12P) by TURP or retropubic adenomectomy. Adenoma samples were routinely stained with HE and later prepared for immunohistochemical studies using CD3, CD20 and CD68 antibodies. Counting of positives cells, lymphoid aggregates and foci were done using EnVision technique and the Tech Mate processor. Cytokines, growth factors and eicosanoids were determined by Elisa kits following the manufactured recommendation.
Results:
Histological: A difference was observed in the number of lymphocytes B between C (91.4±44.1) and P treated (58.2±53.7) groups (
p=0.097).
Biological markers: TNFα and IL-1β were dramatically lower in the Permixon treated group. Other parameters did not show significant changes.
Clinical: IPSS in the Permixon treated group was significantly reduced (
p<0.006) from 20.0+5.9 to 14.9+3.8 after three months of treatment.
Comments:
The BPH inflammatory hypothesis was tested in humans. Our pilot study shows a significant reduction of some inflammatory parameters in prostatic tissues of patients treated with Permixon. These biological findings justify a pharmacological effect of this drug on the inflammatory status of the adenoma. A correlation with clinical improvement was observed.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/S0302-2838(03)00368-3</identifier><identifier>PMID: 14572753</identifier><identifier>CODEN: EUURAV</identifier><language>eng</language><publisher>Oxford: Elsevier B.V</publisher><subject>Adenoma - drug therapy ; Adenoma - pathology ; Adenoma - surgery ; Aged ; Androgen Antagonists - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - blood ; BPH ; Chi-Square Distribution ; Double-Blind Method ; Genital system. Reproduction ; Humans ; Inflammation ; Inflammation Mediators - analysis ; Male ; Medical sciences ; Middle Aged ; Permixon ; Pharmacology. Drug treatments ; Pilot Projects ; Plant Extracts - therapeutic use ; Prostatectomy ; Prostatic Hyperplasia - drug therapy ; Prostatic Hyperplasia - pathology ; Prostatic Hyperplasia - surgery ; Serenoa ; Serenoa repens ; Statistics, Nonparametric ; Treatment Outcome</subject><ispartof>European urology, 2003-11, Vol.44 (5), p.549-555</ispartof><rights>2003 Elsevier B.V.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-8c0d9908adc48ef29eef78d1a36ba934511dc7307f24e39e7356829a72590a6e3</citedby><cites>FETCH-LOGICAL-c391t-8c0d9908adc48ef29eef78d1a36ba934511dc7307f24e39e7356829a72590a6e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283803003683$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15224144$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14572753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vela Navarrete, R</creatorcontrib><creatorcontrib>Garcia Cardoso, J.V</creatorcontrib><creatorcontrib>Barat, A</creatorcontrib><creatorcontrib>Manzarbeitia, F</creatorcontrib><creatorcontrib>López Farré, A</creatorcontrib><title>BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Introduction:
The role of infiltrating cells (I.C.), commonly observed in the adenoma interstitial tissue, is unknown. We tested the hypothesis that I.C. are related with BPH progression by: phenotypically characterising these cells; quantifying the expression of lymphokines and growth factors; investigating the response to Permixon (P) in a clinical study. Permixon is a Lipido Sterolic Extract of Serenoa repens possessing pharmacological activities and widely used in the treatment of men with BPH.
Material and Methods:
A multicenter open pilot study of two parallel groups on BPH patients was carried out. They were randomized to receive either oral Permixon (P) 160
mg bid for three months or to be followed for 3 weeks without any treatment before surgery (control group C). Strict inclusion and exclusion criteria were applied to conform homogeneous groups, avoiding interferences of inflammatory drugs or others. Baseline clinical profile was almost identical in both groups in terms of age (65.7±5.1 vs. 67.1±5.8 years), IPSS (19.8±6.1 vs. 19.0±5.8), prostate volume (64.8±18.9 vs. 71.5±29.3
cc),
Q
max (9.6±3.2 vs. 10.6±2.6
ml/s), and
Q
L (4.0±1.1 vs. 3.5±0.7). Surgery was ultimately performed on 29 patients (17C, 12P) by TURP or retropubic adenomectomy. Adenoma samples were routinely stained with HE and later prepared for immunohistochemical studies using CD3, CD20 and CD68 antibodies. Counting of positives cells, lymphoid aggregates and foci were done using EnVision technique and the Tech Mate processor. Cytokines, growth factors and eicosanoids were determined by Elisa kits following the manufactured recommendation.
Results:
Histological: A difference was observed in the number of lymphocytes B between C (91.4±44.1) and P treated (58.2±53.7) groups (
p=0.097).
Biological markers: TNFα and IL-1β were dramatically lower in the Permixon treated group. Other parameters did not show significant changes.
Clinical: IPSS in the Permixon treated group was significantly reduced (
p<0.006) from 20.0+5.9 to 14.9+3.8 after three months of treatment.
Comments:
The BPH inflammatory hypothesis was tested in humans. Our pilot study shows a significant reduction of some inflammatory parameters in prostatic tissues of patients treated with Permixon. These biological findings justify a pharmacological effect of this drug on the inflammatory status of the adenoma. A correlation with clinical improvement was observed.</description><subject>Adenoma - drug therapy</subject><subject>Adenoma - pathology</subject><subject>Adenoma - surgery</subject><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>BPH</subject><subject>Chi-Square Distribution</subject><subject>Double-Blind Method</subject><subject>Genital system. Reproduction</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation Mediators - analysis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Permixon</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Plant Extracts - therapeutic use</subject><subject>Prostatectomy</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Prostatic Hyperplasia - surgery</subject><subject>Serenoa</subject><subject>Serenoa repens</subject><subject>Statistics, Nonparametric</subject><subject>Treatment Outcome</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1DAUhS0EokPhJ4C8oYJFih9JnLBB7VA6lVox4rG27jjXYHDi1k4Q81_4sXge6iwrWbIX3zm-9xxCXnJ2yhmv331lkolCNLJ5w-RbxmTdFPIRmfFGyUJVNXtMZvfIEXmW0i-WqaqVT8kRLyslVCVn5N_5ckFh6OjVYD30PYwuDO_p8ifEHkzw4Ycz4OmFtWjGRIOlS4y9-xsGms_CpfGe2bjcBI9m8hAPfiGu6Q3E3xjTKf2CafI7H6Afw7TySM-9y8ql82Gk8_zemp2lBOvn5IkFn_DF_j4m3z9dfJsviuvPl1fzs-vCyJaPRWNY17asgc6UDVrRIlrVdBxkvYJWlhXnnVGSKStKlC0qWdWNaEGJqmVQozwmJzvf2xjuJkyj7l0y6D0MGKakFZc5MV5msNqBJoaUIlp9G10Pca0505ta9LYWvclcM6m3tWiZda_2H0yrHruDat9DBl7vAUh5fRthMC4duEqIkpebAT7sOMxx_HEYdTIOB4Odi7kg3QX3wCj_Aeevqq0</recordid><startdate>20031101</startdate><enddate>20031101</enddate><creator>Vela Navarrete, R</creator><creator>Garcia Cardoso, J.V</creator><creator>Barat, A</creator><creator>Manzarbeitia, F</creator><creator>López Farré, A</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031101</creationdate><title>BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay</title><author>Vela Navarrete, R ; Garcia Cardoso, J.V ; Barat, A ; Manzarbeitia, F ; López Farré, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-8c0d9908adc48ef29eef78d1a36ba934511dc7307f24e39e7356829a72590a6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenoma - drug therapy</topic><topic>Adenoma - pathology</topic><topic>Adenoma - surgery</topic><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>BPH</topic><topic>Chi-Square Distribution</topic><topic>Double-Blind Method</topic><topic>Genital system. Reproduction</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation Mediators - analysis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Permixon</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Plant Extracts - therapeutic use</topic><topic>Prostatectomy</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Prostatic Hyperplasia - surgery</topic><topic>Serenoa</topic><topic>Serenoa repens</topic><topic>Statistics, Nonparametric</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vela Navarrete, R</creatorcontrib><creatorcontrib>Garcia Cardoso, J.V</creatorcontrib><creatorcontrib>Barat, A</creatorcontrib><creatorcontrib>Manzarbeitia, F</creatorcontrib><creatorcontrib>López Farré, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vela Navarrete, R</au><au>Garcia Cardoso, J.V</au><au>Barat, A</au><au>Manzarbeitia, F</au><au>López Farré, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2003-11-01</date><risdate>2003</risdate><volume>44</volume><issue>5</issue><spage>549</spage><epage>555</epage><pages>549-555</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><coden>EUURAV</coden><abstract>Introduction:
The role of infiltrating cells (I.C.), commonly observed in the adenoma interstitial tissue, is unknown. We tested the hypothesis that I.C. are related with BPH progression by: phenotypically characterising these cells; quantifying the expression of lymphokines and growth factors; investigating the response to Permixon (P) in a clinical study. Permixon is a Lipido Sterolic Extract of Serenoa repens possessing pharmacological activities and widely used in the treatment of men with BPH.
Material and Methods:
A multicenter open pilot study of two parallel groups on BPH patients was carried out. They were randomized to receive either oral Permixon (P) 160
mg bid for three months or to be followed for 3 weeks without any treatment before surgery (control group C). Strict inclusion and exclusion criteria were applied to conform homogeneous groups, avoiding interferences of inflammatory drugs or others. Baseline clinical profile was almost identical in both groups in terms of age (65.7±5.1 vs. 67.1±5.8 years), IPSS (19.8±6.1 vs. 19.0±5.8), prostate volume (64.8±18.9 vs. 71.5±29.3
cc),
Q
max (9.6±3.2 vs. 10.6±2.6
ml/s), and
Q
L (4.0±1.1 vs. 3.5±0.7). Surgery was ultimately performed on 29 patients (17C, 12P) by TURP or retropubic adenomectomy. Adenoma samples were routinely stained with HE and later prepared for immunohistochemical studies using CD3, CD20 and CD68 antibodies. Counting of positives cells, lymphoid aggregates and foci were done using EnVision technique and the Tech Mate processor. Cytokines, growth factors and eicosanoids were determined by Elisa kits following the manufactured recommendation.
Results:
Histological: A difference was observed in the number of lymphocytes B between C (91.4±44.1) and P treated (58.2±53.7) groups (
p=0.097).
Biological markers: TNFα and IL-1β were dramatically lower in the Permixon treated group. Other parameters did not show significant changes.
Clinical: IPSS in the Permixon treated group was significantly reduced (
p<0.006) from 20.0+5.9 to 14.9+3.8 after three months of treatment.
Comments:
The BPH inflammatory hypothesis was tested in humans. Our pilot study shows a significant reduction of some inflammatory parameters in prostatic tissues of patients treated with Permixon. These biological findings justify a pharmacological effect of this drug on the inflammatory status of the adenoma. A correlation with clinical improvement was observed.</abstract><cop>Oxford</cop><pub>Elsevier B.V</pub><pmid>14572753</pmid><doi>10.1016/S0302-2838(03)00368-3</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0302-2838 |
| ispartof | European urology, 2003-11, Vol.44 (5), p.549-555 |
| issn | 0302-2838 1873-7560 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71314514 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenoma - drug therapy Adenoma - pathology Adenoma - surgery Aged Androgen Antagonists - therapeutic use Biological and medical sciences Biomarkers, Tumor - blood BPH Chi-Square Distribution Double-Blind Method Genital system. Reproduction Humans Inflammation Inflammation Mediators - analysis Male Medical sciences Middle Aged Permixon Pharmacology. Drug treatments Pilot Projects Plant Extracts - therapeutic use Prostatectomy Prostatic Hyperplasia - drug therapy Prostatic Hyperplasia - pathology Prostatic Hyperplasia - surgery Serenoa Serenoa repens Statistics, Nonparametric Treatment Outcome |
| title | BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T16%3A00%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BPH%20and%20Inflammation:%20Pharmacological%20Effects%20of%20Permixon%20on%20Histological%20and%20Molecular%20Inflammatory%20Markers.%20Results%20of%20a%20Double%20Blind%20Pilot%20Clinical%20Assay&rft.jtitle=European%20urology&rft.au=Vela%20Navarrete,%20R&rft.date=2003-11-01&rft.volume=44&rft.issue=5&rft.spage=549&rft.epage=555&rft.pages=549-555&rft.issn=0302-2838&rft.eissn=1873-7560&rft.coden=EUURAV&rft_id=info:doi/10.1016/S0302-2838(03)00368-3&rft_dat=%3Cproquest_cross%3E71314514%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71314514&rft_id=info:pmid/14572753&rft_els_id=S0302283803003683&rfr_iscdi=true |